However, in line with other reports, exposure to ruxolitinib not only promotes BCL6 overexpression in CRLF2-rearranged Ph-like B-ALL cells but also enriches the gene expression signature associated with B-cell differentiation and pre-BCR signaling (Table S1). This evidence concerns the gene BCL6 and acute lymphoblastic leukemia.